News and Trends 11 Oct 2016 UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies Crescendo Biologics, a small UK-based startup, has made an almost €1B deal with Japanese giant Takeda for its Humabody technology. Crescendo Biologics may seem like a small fish, but it has caught the attention of a host of blue-chip investors like Sofinnova Partners. Its Humabody platform has recently attracted the Japanese pharmaceutical giant, Takeda, whose subsidiary, […] October 11, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Big Pharmas Battle to be the Lung Cancer Leader at ESMO Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in lung cancer therapies. The conference of the European Society of Medical Oncology (ESMO) is underway in Copenhagen, and big pharma’s efforts to cure lung cancer are stealing the show. Three titans, Roche (Genentech), Merck and […] October 10, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Overseas Deaths in the Clinic come as a Blow to Boehringer Ingelheim Boehringer Ingelheim has swiftly dumped its olmutinib collaboration with Hanmi following news of deaths in South Korean Phase II trials. An investigation by the South Korean Ministry of Food and Drug Safety has linked several deaths to olmutinib, a lung cancer drug launched by Hanmi. Sound familiar? Boehringer Ingelheim just signed a deal to acquire the […] October 10, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 New UK Hero Will Fight Against Non-Small Cell Lung Cancer Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […] October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 A new Immuno-Oncology biotech’s Small Molecule hits the Clinic Since we interviewed Karus Therapeutics last year, the company has come quite a way! The Oxford-based biotech has just sent its first drug to the clinic. We first met Karus Therapeutics a year ago to talk about their small molecule therapies for cancer and inflammatory disease. The company has entered the immuno-oncology fray and is developing a […] October 6, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 €365M deal for a Danish ‘DNA barcode’ Drug Screening Platform The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 A Secretive new Oncology Biotech has made a Dramatic Debut Carrick Therapeutics has burst onto the oncology scene with a massive round of fundraising, reeling in almost €100M to become Europe’s cancer leader. Since its foundation last year, oncology upstart Carrick Therapeutics has mostly stayed off the radar. That changed yesterday, when it announced a splashy fundraising round of €85M ($95M) to propel it to the top of […] October 4, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Boehringer buys a €210M ticket to Virus-based Immuno-Oncology Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […] September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Titans in Gene Therapy and TCRs make a Massive Deal Medigene has licensed a few candidates from its TCR platform to one of the Boston ‘it’ biotechs in a deal totaling around €1B. By partnering with bluebird bio, Medigene is reestablishing itself as a leader in immuno-oncology. Founded over 20 years ago, Medigene has risen to the top of the European biotech scene with a […] September 29, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Debunking the Immuno-Oncology Hype: is it as good as it sounds? CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […] September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2016 Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […] September 28, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 SELLAS wants to sell us an Immunotherapy for Mesothelioma After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […] September 23, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email